NASDAQ:CFMS - ConforMIS Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.54 +0.02 (+3.85 %) (As of 11/16/2018 08:00 AM ET)Previous Close$0.52Today's Range$0.53 - $0.5752-Week Range$0.52 - $3.35Volume424,800 shsAverage Volume309,736 shsMarket Capitalization$37.33 millionP/E RatioN/ADividend YieldN/ABeta1.23 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email ConforMIS, Inc., a medical technology company, develops, manufactures, and sells joint replacement implants. The company offers customized knee replacement products, including iTotal CR, a cruciate-retaining product; iTotal PS, a posterior cruciate ligament substituting product; iDuo, a customized bicompartmental knee replacement system; and iUni, a customized unicompartmental knee replacement product to treat the medial or lateral compartment of the knee. It also provides ConforMIS Hip System, a hip replacement product; and iJigs, a customized single-use patient-specific instrumentation. The company markets and sells its products to hospitals and other medical facilities through sales force, independent sales representatives, and distributors in the United States, Germany, the United Kingdom, Austria, Ireland, Switzerland, Singapore, Hong Kong, Malaysia, and Monaco. ConforMIS, Inc. was founded in 2004 and is headquartered in Billerica, Massachusetts. Receive CFMS News and Ratings via Email Sign-up to receive the latest news and ratings for CFMS and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical appliances & supplies Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CFMS Previous Symbol CUSIPN/A Webwww.conformis.com Phone781-345-9001 Debt Debt-to-Equity Ratio0.68 Current Ratio5.71 Quick Ratio4.91 Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$78.11 million Price / Sales0.44 Cash FlowN/A Price / CashN/A Book Value$0.69 per share Price / Book0.78 Profitability EPS (Most Recent Fiscal Year)($1.24) Net Income$-53,580,000.00 Net Margins-51.25% Return on Equity-90.97% Return on Assets-47.94% Miscellaneous Employees350 Outstanding Shares63,270,000Market Cap$37.33 million OptionableNot Optionable ConforMIS (NASDAQ:CFMS) Frequently Asked Questions What is ConforMIS's stock symbol? ConforMIS trades on the NASDAQ under the ticker symbol "CFMS." How were ConforMIS's earnings last quarter? ConforMIS Inc (NASDAQ:CFMS) announced its quarterly earnings data on Wednesday, October, 31st. The medical instruments supplier reported ($0.12) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.20) by $0.08. The medical instruments supplier had revenue of $28.98 million for the quarter, compared to analysts' expectations of $19.21 million. ConforMIS had a negative return on equity of 90.97% and a negative net margin of 51.25%. View ConforMIS's Earnings History. When is ConforMIS's next earnings date? ConforMIS is scheduled to release their next quarterly earnings announcement on Wednesday, February 6th 2019. View Earnings Estimates for ConforMIS. What guidance has ConforMIS issued on next quarter's earnings? ConforMIS issued an update on its FY 2018 earnings guidance on Wednesday, October, 31st. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $77.5-78 million, compared to the consensus revenue estimate of $80.34 million. What price target have analysts set for CFMS? 6 analysts have issued twelve-month target prices for ConforMIS's stock. Their predictions range from $2.50 to $3.00. On average, they expect ConforMIS's stock price to reach $2.8750 in the next year. This suggests a possible upside of 432.4% from the stock's current price. View Analyst Price Targets for ConforMIS. What is the consensus analysts' recommendation for ConforMIS? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ConforMIS in the last year. There are currently 1 sell rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ConforMIS. What are Wall Street analysts saying about ConforMIS stock? Here are some recent quotes from research analysts about ConforMIS stock: 1. According to Zacks Investment Research, "ConforMIS, Inc. is a medical technology company which develops, manufacture and sells joint replacement implants. The Company's iFit technology platform consists of iFit Design, iFit Printing and iFit Just-in-Time Delivery. It operates primarily in the United States, Germany and the United Kingdom. The Company serves orthopedic surgeons, hospitals and other medical facilities and patients. ConforMIS, Inc. is based in Bedford, United States. " (11/5/2018) 2. BTIG Research analysts commented, "Ongoing OUS Headwinds While CFMS 2Q18 results were a bit below our expectations (rev. of $19.1M (+3% Y/Y,+2% xFx) vs. BTIG/Consensus of $19.3M/$19.4M respectively, product rev. increased Y/Y for the first time since 1Q17, growing 5% to $18.0M. Mgmt. is making progress on US commercialization (albeit slower than investors will prefer). OUS continues to be challenged in Germany but mgmt. noted recent OUS sales leadership hires that may open up a few countries in 2H18. Mgmt. commentary on payor acceptance of CFMS products indicates increasing positive traction amongst some payers but CFMS is still not where it wants to be on rep growth, which missed the 20% growth target slightly. On the call, mgmt. announced plans to reduce OpEx while shuffling its product pipeline around." (8/2/2018) Has ConforMIS been receiving favorable news coverage? Headlines about CFMS stock have been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. ConforMIS earned a media sentiment score of 0.5 on InfoTrie's scale. They also gave media coverage about the medical instruments supplier a news buzz of 5.0 out of 10, indicating that recent press coverage is somewhat likely to have an impact on the company's share price in the near term. Who are some of ConforMIS's key competitors? Some companies that are related to ConforMIS include Lakeland Industries (LAKE), Rewalk Robotics (RWLK), COLLPLANT HOLDI/S (CLGN), NanoVibronix (NAOV), Histogenics (HSGX), Precision Therapeutics (AIPT), Wound Management Technologies (WNDM), Allied Healthcare Products (AHPI), Avitar (AVTI), Bionik Laboratories (BNKL) and Halyard Health (HYH). Who are ConforMIS's key executives? ConforMIS's management team includes the folowing people: Mr. Mark A. Augusti, CEO, Pres & Director (Age 52)Mr. Paul S. Weiner CPA, CFO & Treasurer (Age 54)Dr. Daniel Steines M.D., MS, Consultant (Age 49)Mr. Ed Kilgallen, VP of OperationsMs. Patricia A. Davis J.D., Chief Legal Officer, Gen. Counsel & Corp. Sec. (Age 52) When did ConforMIS IPO? (CFMS) raised $135 million in an initial public offering on Wednesday, July 1st 2015. The company issued 9,000,000 shares at $14.00-$16.00 per share. J.P. Morgan and Deutsche Bank Securities served as the underwriters for the IPO and Wells Fargo Securities and Canaccord Genuity were co-managers. Who are ConforMIS's major shareholders? ConforMIS's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (5.23%), Sio Capital Management LLC (2.94%) and Laurion Capital Management LP (0.19%). Company insiders that own ConforMIS stock include Bradley Langdale, Daniel Steines, David Cerveny, Mark A Augusti, Paul S Weiner and Philipp Lang. View Institutional Ownership Trends for ConforMIS. Which major investors are selling ConforMIS stock? CFMS stock was sold by a variety of institutional investors in the last quarter, including Laurion Capital Management LP. Company insiders that have sold ConforMIS company stock in the last year include Bradley Langdale, Daniel Steines, David Cerveny, Mark A Augusti, Paul S Weiner and Philipp Lang. View Insider Buying and Selling for ConforMIS. Which major investors are buying ConforMIS stock? CFMS stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC and Sio Capital Management LLC. View Insider Buying and Selling for ConforMIS. How do I buy shares of ConforMIS? Shares of CFMS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is ConforMIS's stock price today? One share of CFMS stock can currently be purchased for approximately $0.54. How big of a company is ConforMIS? ConforMIS has a market capitalization of $37.33 million and generates $78.11 million in revenue each year. The medical instruments supplier earns $-53,580,000.00 in net income (profit) each year or ($1.24) on an earnings per share basis. ConforMIS employs 350 workers across the globe. What is ConforMIS's official website? The official website for ConforMIS is http://www.conformis.com. How can I contact ConforMIS? ConforMIS's mailing address is 600 TECHNOLOGY PARK DRIVE, BILLERICA MA, 01821. The medical instruments supplier can be reached via phone at 781-345-9001 or via email at [email protected] MarketBeat Community Rating for ConforMIS (NASDAQ CFMS)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 257 (Vote Outperform)Underperform Votes: 198 (Vote Underperform)Total Votes: 455MarketBeat's community ratings are surveys of what our community members think about ConforMIS and other stocks. Vote "Outperform" if you believe CFMS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CFMS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 11/16/2018 by MarketBeat.com StaffFeatured Article: Why is the conference call important?